NumberRecommendationSee section
Provision of information
1Pregnant women should be offered evidence-based information and support to enable them to make informed decisions about childbirth. Addressing women's views and concerns should be recognised as being integral to the decision-making process. [C] [2004]4.1
2Give pregnant women evidence-based information about CS during the antenatal period, because about 1 in 4 women will have a CS. Include information about CS, such as:
  • indications for CS (such as presumed fetal compromise, ‘failure to progress’ in labour, breech presentation)
  • what the procedure involves
  • associated risks and benefits
  • implications for future pregnancies and birth after CS. [GPP] [new 2011]
3Communication and information should be provided in a form that is accessible to pregnant women, taking into account the information and cultural needs of minority communities and women whose first language is not English or who cannot read, together with the needs of women with disabilities or learning difficulties. [GPP] [2004]4.1
Planning mode of birth
4Discuss the risks and benefits of CS compared with vaginal birth with women (see tables 4.5 and 4.6, and also recommendation 118), taking into account their circumstances, concerns, priorities and plans for future pregnancies (including the risks of placental problems with multiple CS). [new 2011]4.2
5Do not use a body mass index (BMI) of over 50 alone as an indication for planned CS. [new 2011]4.2
6Consent for CS should be requested after providing pregnant women with evidence-based information and in a manner that respects the woman's dignity, privacy, views and culture, while taking into consideration the clinical situation. [C] [2004]4.2
7A pregnant woman is entitled to decline the offer of treatment such as CS, even when the treatment would clearly benefit her or her baby's health. Refusal of treatment needs to be one of the woman's options. [D] [2004]4.2
8When a decision is made to perform a CS, a record should be made of all the factors that influence the decision, and which of these is the most influential. [GPP] [2004]4.2
Breech presentation
9Women who have an uncomplicated singleton breech pregnancy at 36 weeks' gestation should be offered external cephalic version. Exceptions include women in labour and women with a uterine scar or abnormality, fetal compromise, ruptured membranes, vaginal bleeding or medical conditions. [A] [2004]5.1
10Pregnant women with a singleton breech presentation at term, for whom external cephalic version is contraindicated or has been unsuccessful, should be offered CS because it reduces perinatal mortality and neonatal morbidity. [A] [2004]5.1
Multiple pregnancy
11In otherwise uncomplicated twin pregnancies at term where the presentation of the first twin is cephalic, perinatal morbidity and mortality is increased for the second twin. However, the effect of planned CS in improving outcome for the second twin remains uncertain and therefore CS should not routinely be offered outside a research context. [C] [2004]5.2
12In twin pregnancies where the first twin is not cephalic the effect of CS in improving outcome is uncertain, but current practice is to offer a planned CS. [GPP] [2004]5.2
Preterm birth and CS
13Preterm birth is associated with higher neonatal morbidity and mortality. However, the effect of planned CS in improving these outcomes remains uncertain and therefore CS should not routinely be offered outside a research context. [C] [2004]5.3
Small for gestational age
14The risk of neonatal morbidity and mortality is higher with ‘small for gestational age’ babies. However, the effect of planned CS in improving these outcomes remains uncertain and therefore CS should not routinely be offered outside a research context. [C] [2004]5.4
Placenta praevia
15Women with a placenta that partly or completely covers the internal cervical os (minor or major placenta praevia) should be offered CS. [D] [2004]5.5
Morbidly adherent placenta
16If low-lying placenta is confirmed at 32–34 weeks in women who have had a previous CS, offer colour-flow Doppler ultrasound as the first diagnostic test for morbidly adherent placenta. [new 2011]5.6
17If a colour-flow Doppler ultrasound scan result suggests morbidly adherent placenta:
  • discuss with the woman the improved accuracy of magnetic resonance imaging (MRI) in addition to ultrasound to help diagnose morbidly adherent placenta and clarify the degree of invasion
  • explain what to expect during an MRI procedure
  • inform the woman that current experience suggests that MRI is safe, but that there is a lack of evidence about any long term risks to the baby
  • offer MRI if acceptable to the woman. [new 2011]
18Discuss the interventions available for delivery with women suspected to have morbidly adherent placenta, including cross matching of blood and planned CS with a consultant obstetrician present. [new 2011]5.6
19When performing a CS for women suspected to have morbidly adherent placenta, ensure that:
  • a consultant obstetrician and a consultant anaesthetist are present
  • an experienced paediatrician is present
  • a senior haematologist is available for advice
  • a critical care bed is available
  • sufficient cross-matched blood and blood products are readily available. [new 2011]
20When performing a CS for women suspected to have morbidly adherent placenta the consultant obstetrician should decide which other healthcare professionals need to be consulted or present. [new 2011]5.6
21All hospitals should have a locally agreed protocol for managing morbidly adherent placenta that sets out how these elements of care should be provided. [new 2011]5.6
Predicting CS for cephalopelvic disproportion in labour
22Pelvimetry is not useful in predicting ‘failure to progress’ in labour and should not be used in decision making about mode of birth. [A] [2004]5.7
23Shoe size, maternal height and estimations of fetal size (ultrasound or clinical examination) do not accurately predict cephalopelvic disproportion and should not be used to predict ‘failure to progress’ during labour. [B] [2004]5.7
Mother-to-child transmission of maternal infections
24As early as possible give women with HIV information about the risks and benefits for them and their child of the HIV treatment options and mode of birth so that they can make an informed decision. [new 2011]5.8
25Do not offer a CS on the grounds of HIV status to prevent mother-to-child transmission of HIV to:
  • women on highly active anti-retroviral therapy (HAART) with a viral load of less than 400 copies per ml or
  • women on any anti-retroviral therapy with a viral load of less than 50 copies per ml.
Inform women that in these circumstances the risk of HIV transmission is the same for a CS and a vaginal birth. [new 2011]
26Consider either a vaginal birth or a CS for women on anti-retroviral therapy (ART) with a viral load of 50–400 copies per ml because there is insufficient evidence that a CS prevents mother-to-child transmission of HIV. [new 2011]5.8
27Offer a CS to women with HIV who:
  • are not receiving any anti-retroviral therapy or
  • are receiving any anti-retroviral therapy and have a viral load of 400 copies per ml or more. [new 2011]
28Researchers and national bodies responsible for the collection of UK population data should continue to collect data about HIV diagnoses in pregnant women, including treatment, mode of birth, and mother-to-child transmission rates. [new 2011]5.8
29Mother-to-child transmission of hepatitis B can be reduced if the baby receives immunoglobulin and vaccination. In these situations pregnant women with hepatitis B should not be offered a planned CS because there is insufficient evidence that this reduces mother-to-child transmission of hepatitis B virus. [B] [2004]5.8
30Women who are infected with hepatitis C should not be offered a planned CS because this does not reduce mother-to-child transmission of the virus. [C] [2004]5.8
31Pregnant women who are co-infected with hepatitis C virus and HIV should be offered planned CS because it reduces mother-to-child transmission of both hepatitis C virus and HIV. [C] [2004]5.8
32Women with primary genital herpes simplex virus (HSV) infection occurring in the third trimester of pregnancy should be offered planned CS because it decreases the risk of neonatal HSV infection. [C] [2004]5.8
33Pregnant women with a recurrence of HSV at birth should be informed that there is uncertainty about the effect of planned CS in reducing the risk of neonatal HSV infection. Therefore, CS should not routinely be offered outside a research context. [C] [2004]5.8
Maternal request for CS
34When a woman requests a CS explore, discuss and record the specific reasons for the request. [new 2011]5.9
35If a woman requests a CS when there is no other indication, discuss the overall risks and benefits of CS compared with vaginal birth (see tables 4.5 and 4.6) and record that this discussion has taken place. Include a discussion with other members of the obstetric team (including the obstetrician, midwife and anaesthetist) if necessary to explore the reasons for the request, and to ensure the woman has accurate information. [new 2011]5.9
36When a woman requests a CS because she has anxiety about childbirth, offer referral to a healthcare professional with expertise in providing perinatal mental health support to help her address her anxiety in a supportive manner. [new 2011]5.9
37Ensure the healthcare professional providing perinatal mental health support has access to the planned place of birth during the antenatal period in order to provide care. [new 2011]5.9
38For women requesting a CS, if after discussion and offer of support (including perinatal mental health support for women with anxiety about childbirth), a vaginal birth is still not an acceptable option, offer a planned CS. [new 2011]5.9
39An obstetrician unwilling to perform a CS should refer the woman to an obstetrician who will carry out the CS. [new 2011]5.9
42Women should be informed that continuous support during labour from women with or without prior training reduces the likelihood of CS. [A] [2004]6.2
43Women with an uncomplicated pregnancy should be offered induction of labour beyond 41 weeks because this reduces the risk of perinatal mortality and the likelihood of CS. [A] [2004]6.2
44A partogram with a 4-hour action line should be used to monitor progress of labour of women in spontaneous labour with an uncomplicated singleton pregnancy at term, because it reduces the likelihood of CS. [A] [2004]6.2
45Consultant obstetricians should be involved in the decision making for CS, because this reduces the likelihood of CS. [C] [2004]
46Electronic fetal monitoring is associated with an increased likelihood of CS. When CS is contemplated because of an abnormal fetal heart rate pattern, in cases of suspected fetal acidosis, fetal blood sampling should be offered if it is technically possible and there are no contraindications. [B] [2004]
No influence on likelihood of CS
47Women should be informed that the following interventions during intrapartum care have not been shown to influence the likelihood of CS, although they may affect other outcomes that are outside the scope of this guideline:
  • walking in labour
  • non-supine position during the second stage of labour
  • immersion in water during labour
  • epidural analgesia during labour
  • the use of raspberry leaves. [A] [2004]
48Women should be informed that the effects on the likelihood of CS of complementary therapies used during labour (such as acupuncture, aromatherapy, hypnosis, herbal products, nutritional supplements, homeopathic medicines, and Chinese medicines) have not been properly evaluated and further research is needed before such interventions can be recommended. [D] [2004]6.3
‘Failure to progress’ in labour and CS
49The following aspects of intrapartum care have not been shown to influence the likelihood of CS for ‘failure to progress’ and should not be offered for this reason, although they may affect other outcomes which are outside the scope of this guideline:
  • active management of labour
  • early amniotomy. [A] [2004]
Eating during labour
50Women should be informed that eating a low-residue diet during labour (toast, crackers, low-fat cheese) results in larger gastric volumes, but the effect on the risk of aspiration if anaesthesia is required is uncertain. [A] [2004]6.5
51Women should be informed that having isotonic drinks during labour prevents ketosis without a concomitant increase in gastric volume. [A] [2004]6.5
Timing of planned CS
52The risk of respiratory morbidity is increased in babies born by CS before labour, but this risk decreases significantly after 39 weeks. Therefore planned CS should not routinely be carried out before 39 weeks. [B] [2004]7.1
Classification of urgency
53The urgency of CS should be documented using the following standardised scheme in order to aid clear communication between healthcare professionals about the urgency of a CS:
  1. immediate threat to the life of the woman or fetus
  2. maternal or fetal compromise which is not immediately life-threatening
  3. no maternal or fetal compromise but needs early delivery
  4. delivery timed to suit woman or staff. [C] [2004]
Decision-to-delivery interval for unplanned CS
54Perform category 1 and 2 CS (see recommendation 53) as quickly as possible after making the decision, particularly for category 1. [new 2011]7.3
55Perform category 2 CS in most situations within 75 minutes of making the decision. [new 2011]7.3
56Take into account the condition of the woman and the unborn baby when making decisions about rapid delivery. Remember that rapid delivery may be harmful in certain circumstances. [new 2011]7.3
57Use the following decision to delivery intervals to measure the overall performance of an obstetric unit:
  • 30 minutes for category 1 CS
  • both 30 and 75 minutes for category 2 CS.
Use these as audit standards only and not to judge multidisciplinary team performance for any individual CS. [new 2011]
Preoperative testing and preparation for CS
58Pregnant women should be offered a haemoglobin assessment before CS to identify those who have anaemia. Although blood loss of more than 1000 ml is infrequent after CS (it occurs in 4-8% of CS) it is a potentially serious complication. [C] [2004]7.4
59Pregnant women having CS for antepartum haemorrhage, abruption, uterine rupture and placenta praevia are at increased risk of blood loss of more than 1000 ml and should have the CS carried out at a maternity unit with on-site blood transfusion services. [C] [2004]7.4
60Pregnant women who are healthy and who have otherwise uncomplicated pregnancies should not routinely be offered the following tests before CS:
  • grouping and saving of serum
  • cross-matching of blood
  • a clotting screen
  • preoperative ultrasound for localisation of the placenta, because this does not improve CS morbidity outcomes (such as blood loss of more than 1000 ml, injury of the infant, and injury to the cord or to other adjacent structures). [C] [2004]
61Women having CS with regional anaesthesia require an indwelling urinary catheter to prevent over-distension of the bladder because the anaesthetic block interferes with normal bladder function. [GPP] [2004]7.4
Anaesthesia for CS
62Pregnant women having a CS should be given information on different types of post-CS analgesia so that analgesia best suited to their needs can be offered (see recommendation 104). [GPP] [2004]7.5
63Women who are having a CS should be offered regional anaesthesia because it is safer and results in less maternal and neonatal morbidity than general anaesthesia. This includes women who have a diagnosis of placenta praevia. [A] [2004]7.5
64Women who are having induction of regional anaesthesia for CS should be cared for in theatre because this does not increase women's anxiety. [B] [2004]7.5
65Women who are having a CS under regional anaesthesia should be offered intravenous ephedrine or phenylephrine, and volume preloading with crystalloid or colloid to reduce the risk of hypotension occurring during CS. [A] [2004]7.5
66Each maternity unit should have a drill for failed intubation during obstetric anaesthesia. [D] [2004]7.5
67To reduce the risk of aspiration pneumonitis women should be offered antacids and drugs (such as H2 receptor antagonists or proton pump inhibitors) to reduce gastric volumes and acidity before CS. [B] [2004]7.5
68Women having a CS should be offered antiemetics (either pharmacological or acupressure) to reduce nausea and vomiting during CS. [A] [2004]7.5
69General anaesthesia for unplanned CS should include preoxygenation, cricoid pressure and rapid sequence induction to reduce the risk of aspiration. [GPP] [2004]7.5
70Intravenous ephedrine or phenylephrine should be used in the management of hypotension during CS. [A] [2004]7.5
71The operating table for CS should have a lateral tilt of 15°, because this reduces maternal hypotension. [A] [2004]7.5
Surgical techniques for CS
72Healthcare professionals should wear double gloves when performing or assisting at CS on women who have tested positive for HIV, to reduce the risk of HIV infection of healthcare professionals during surgery. [A] [2004]7.6
73General recommendations for safe surgical practice should be followed at CS to reduce the risk of HIV infection of staff. [C] [2004]7.6
74CS should be performed using a transverse abdominal incision because this is associated with less postoperative pain and an improved cosmetic effect compared with a midline incision. [B] [2004]7.6
75The transverse incision of choice should be the Joel Cohen incision (a straight skin incision, 3 cm above the symphysis pubis; subsequent tissue layers are opened bluntly and, if necessary, extended with scissors and not a knife), because it is associated with shorter operating times and reduced postoperative febrile morbidity. [A] [2004]7.6
76The use of separate surgical knives to incise the skin and the deeper tissues at CS is not recommended because it does not decrease wound infection. [B] [2004]7.6
77When there is a well formed lower uterine segment, blunt rather than sharp extension of the uterine incision should be used because it reduces blood loss, incidence of postpartum haemorrhage and the need for transfusion at CS. [A] [2004]7.6
78Women who are having a CS should be informed that the risk of fetal lacerations is about 2%. [C] [2004]7.6
79Forceps should only be used at CS if there is difficulty delivering the baby's head. The effect on neonatal morbidity of the routine use of forceps at CS remains uncertain. [C] [2004]7.6
80Oxytocin 5 IU by slow intravenous injection should be used at CS to encourage contraction of the uterus and to decrease blood loss. [C] [2004]7.6
81At CS, the placenta should be removed using controlled cord traction and not manual removal as this reduces the risk of endometritis. [A] [2004]7.6
82Intraperitoneal repair of the uterus at CS should be undertaken. Exteriorisation of the uterus is not recommended because it is associated with more pain and does not improve operative outcomes such as haemorrhage and infection. [A] [2004]7.6
83The effectiveness and safety of single layer closure of the uterine incision is uncertain. Except within a research context, the uterine incision should be sutured with two layers. [B] [2004]7.6
84Neither the visceral nor the parietal peritoneum should be sutured at CS because this reduces operating time and the need for postoperative analgesia, and improves maternal satisfaction. [A] [2004]7.6
85In the rare circumstances that a midline abdominal incision is used at CS, mass closure with slowly absorbable continuous sutures should be used because this results in fewer incisional hernias and less dehiscence than layered closure. [B] [2004]7.6
86Routine closure of the subcutaneous tissue space should not be used, unless the woman has more than 2 cm subcutaneous fat, because it does not reduce the incidence of wound infection. [A] [2004]7.6
87Superficial wound drains should not be used at CS because they do not decrease the incidence of wound infection or wound haematoma. [A] [2004]7.6
88Obstetricians should be aware that the effects of different suture materials or methods of skin closure at CS are not certain. [C] [2004]7.6
89Umbilical artery pH should be performed after all CS for suspected fetal compromise, to allow review of fetal wellbeing and guide ongoing care of the baby. [B] [2004]7.6
90Offer women prophylactic antibiotics at CS before skin incision. Inform them that this reduces the risk of maternal infection more than prophylactic antibiotics given after skin incision, and that no effect on the baby has been demonstrated [new 2011]7.6
91Offer women prophylactic antibiotics at CS to reduce the risk of postoperative infections. Choose antibiotics effective against endometritis, urinary tract and wound infections, which occur in about 8% of women who have had a CS. [A] [2004, amended 2011]7.6
92Do not use co-amoxiclav when giving antibiotics before skin incision [new 2011]
93Women having a CS should be offered thromboprophylaxis because they are at increased risk of venous thromboembolism. The choice of method of prophylaxis (for example, graduated stockings, hydration, early mobilisation, low molecular weight heparin) should take into account risk of thromboembolic disease and follow existing guidelines. [D] [2004]*7.6
94Women's preferences for the birth, such as music playing in theatre, lowering the screen to see the baby born, or silence so that the mother's voice is the first the baby hears, should be accommodated where possible. [GPP] [2004]7.6
Presence of paediatrician at CS
95An appropriately trained practitioner skilled in the resuscitation of the newborn should be present at CS performed under general anaesthesia or where there is evidence of fetal compromise. [C] [2004]8.1
Thermal care for babies born by CS
96Babies born by CS are more likely to have a lower temperature, and thermal care should be in accordance with good practice for thermal care of the newborn baby. [GPP] [2004]8.4
Maternal contact (skin-to-skin)
97Early skin-to-skin contact between the woman and her baby should be encouraged and facilitated because it improves maternal perceptions of the infant, mothering skills, maternal behaviour, and breastfeeding outcomes, and reduces infant crying. [A] [2004]8.5
98Women who have had a CS should be offered additional support to help them to start breastfeeding as soon as possible after the birth of their baby. This is because women who have had a CS are less likely to start breastfeeding in the first few hours after the birth, but, when breastfeeding is established, they are as likely to continue as women who have a vaginal birth. [A] [2004]8.6
HDU/ITU admission
99Healthcare professionals caring for women after CS should be aware that, although it is rare for women to need intensive care following childbirth, this occurs more frequently after CS (about 9 per 1000). [B] [2004]9
Routine monitoring after CS
100After CS, women should be observed on a one-to-one basis by a properly trained member of staff until they have regained airway control and cardiorespiratory stability and are able to communicate. [D] [2004]9.1
101After recovery from anaesthesia, observations (respiratory rate, heart rate, blood pressure, pain and sedation) should be continued every half hour for 2 hours, and hourly thereafter provided that the observations are stable or satisfactory. If these observations are not stable, more frequent observations and medical review are recommended. [GPP] [2004]9.1
102For women who have had intrathecal opioids, there should be a minimum hourly observation of respiratory rate, sedation and pain scores for at least 12 hours for diamorphine and 24 hours for morphine. [GPP] [2004]9.1
103For women who have had epidural opioids or patient-controlled analgesia with opioids, there should be routine hourly monitoring of respiratory rate, sedation and pain scores throughout treatment and for at least 2 hours after discontinuation of treatment. [GPP] [2004]9.1
Pain management after CS
104Women should be offered diamorphine (0.3–0.4 mg intrathecally) for intra- and postoperative analgesia because it reduces the need for supplemental analgesia after a CS. Epidural diamorphine (2.5–5 mg) is a suitable alternative. [A] [2004]9.2
105Patient-controlled analgesia using opioid analgesics should be offered after CS because it improves pain relief. [GPP] [2004]9.2
106Providing there is no contraindication, non-steroidal anti­inflammatory drugs should be offered post-CS as an adjunct to other analgesics, because they reduce the need for opioids. [A] [2004]9.2
Early eating and drinking after CS
107Women who are recovering well after CS and who do not have complications can eat and drink when they feel hungry or thirsty. [A] [2004]9.3
Urinary catheter removal after CS
108Removal of the urinary bladder catheter should be carried out once a woman is mobile after a regional anaesthetic and not sooner than 12 hours after the last epidural ‘top up’ dose. [D] [2004]9.4
Respiratory physiotherapy after CS
109Routine respiratory physiotherapy does not need to be offered to women after a CS under general anaesthesia, because it does not improve respiratory outcomes such as coughing, phlegm, body temperature, chest palpation and auscultatory changes. [A] [2004]9.5
Length of hospital stay and readmission to hospital
110Length of hospital stay is likely to be longer after a CS (an average of 3–4 days) than after a vaginal birth (average 1–2 days). However, women who are recovering well, are apyrexial and do not have complications following CS should be offered early discharge (after 24 hours) from hospital and follow-up at home, because this is not associated with more infant or maternal readmissions. [A] [2004]9.7
Recovery following CS
111In addition to general postnatal care, women who have had a CS should be provided with:
  • specific care related to recovery after CS
  • care related to management of other complications during pregnancy or childbirth. [GPP] [2004]
112Women who have a CS should be prescribed and encouraged to take regular analgesia for postoperative pain, using:
  • for severe pain, co-codamol with added ibuprofen
  • for moderate pain, co-codamol
  • for mild pain, paracetamol. [D] [2004]
113CS wound care should include:
  • removing the dressing 24 hours after the CS
  • specific monitoring for fever
  • assessing the wound for signs of infection (such as increasing pain, redness or discharge), separation or dehiscence
  • encouraging the woman to wear loose, comfortable clothes and cotton underwear
  • gently cleaning and drying the wound daily
  • if needed, planning the removal of sutures or clips.1 [D] [2004]
114Healthcare professionals caring for women who have had a CS and who have urinary symptoms should consider the possible diagnosis of:
115Healthcare professionals caring for women who have had a CS and who have heavy and/or irregular vaginal bleeding should consider that this is more likely to be due to endometritis than retained products of conception. [D] [2004, amended 2011]10
116Women who have had a CS are at increased risk of thromboembolic disease (both deep vein thrombosis and pulmonary embolism), so healthcare professionals need to pay particular attention to women who have chest symptoms (such as cough or shortness of breath) or leg symptoms (such as painful swollen calf). [D] [2004]10
117Women who have had a CS should resume activities such as driving a vehicle, carrying heavy items, formal exercise and sexual intercourse once they have fully recovered from the CS (including any physical restrictions or distracting effect due to pain). [GPP] [2004]10
118Healthcare professionals caring for women who have had a CS should inform women that after a CS they are not at increased risk of difficulties with breastfeeding, depression, post-traumatic stress symptoms, dyspareunia and faecal incontinence. [D] [2004]10
Pregnancy and childbirth after CS
119When advising about the mode of birth after a previous CS consider:
  • maternal preferences and priorities
  • the risks and benefits of repeat CS.
  • the risks and benefits of planned vaginal birth after CS, including the risk of unplanned CS [new 2011]
120Inform women who have had up to and including four CS that the risk of fever, bladder injuries and surgical injuries does not vary with planned mode of birth and that the risk of uterine rupture, although higher for planned vaginal birth, is rare. [new 2011]11.2
121Offer women planning a vaginal birth who have had a previous CS:
  • electronic fetal monitoring during labour
  • care during labour in a unit where there is immediate access to CS and on-site blood transfusion services. [GPP] [2011]
122During induction of labour, women who have had a previous CS should be monitored closely, with access to electronic fetal monitoring and with immediate access to CS, because they are at increased risk of uterine rupture. [GPP] [2004]11.2
123Pregnant women with both previous CS and a previous vaginal birth should be informed that they have an increased likelihood of achieving a vaginal birth than women who have had a previous CS but no previous vaginal birth. [B] [2004]11.2
124While women are in hospital after having a CS, give them the opportunity to discuss with healthcare professionals the reasons for the CS and provide both verbal and printed information about birth options for any future pregnancies. If the woman prefers, provide this at a later date. [new 2011]11.2

See also the NICE guideline “Venous thromboembolism - reducing the risk” (NICE CG92, 2010)

From: 1, Guideline summary

Cover of Caesarean Section
Caesarean Section.
NICE Clinical Guidelines, No. 132.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2011 Nov.
Copyright © 2011, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK []. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.